
Ipsen & Biomunex Sign Global Deal for MAIT Cell Engager in Immuno-Oncology
Ipsen and Biomunex Pharmaceuticals have entered into an exclusive global licensing agreement for BMX-502, a promising bispecific antibody designed to target and activate Mucosal-Associated Invariant T cells (MAIT cells) to combat cancer. BMX-502 is specifically engineered to target the GPC3…